Avadel Pharmaceuticals PLC
NASDAQ:AVDL

Watchlist Manager
Avadel Pharmaceuticals PLC Logo
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Watchlist
Price: 8.01 USD -1.35% Market Closed
Market Cap: 774m USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one AVDL stock under the Base Case scenario is 13.8 USD. Compared to the current market price of 8.01 USD, Avadel Pharmaceuticals PLC is Undervalued by 42%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AVDL Relative Value
Base Case
13.8 USD
Undervaluation 42%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4.6
P/S
P/S
Price to Sales
4.6
vs History
55
vs Industry
27
Median 3Y
4.6
Median 5Y
6.8
Industry
2.4
Forward
3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-7.1
Median 5Y
-7.6
Industry
20.8
Forward
85.6
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-9.9
Median 5Y
-8.9
Industry
15.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-7.4
Median 5Y
-7.7
Industry
22.8
More Details
10.5
P/B
P/B
Price to Book Value
10.5
vs History
25
vs Industry
5
Median 3Y
8.4
Median 5Y
5.1
Industry
2
More Details
4.1
EV/S
EV/S
Enterprise Value to Sales
4.1
vs History
57
vs Industry
28
Median 3Y
4.2
Median 5Y
5.8
Industry
2.5
Forward
2.7
More Details
4.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.5
vs History
57
vs Industry
42
Median 3Y
4.6
Median 5Y
7.6
Industry
4.9
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-8.3
Median 5Y
-8.3
Industry
12.7
Forward
25.4
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-8.2
Median 5Y
-8.2
Industry
15.8
Forward
46.8
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-9.1
Median 5Y
-8
Industry
14
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-9.1
Median 5Y
-8
Industry
18.3
More Details
8.4
EV/IC
EV/IC
Enterprise Value to IC
8.4
vs History
42
vs Industry
10
Median 3Y
16.6
Median 5Y
8.3
Industry
1.7
More Details

Multiples Across Competitors

AVDL Competitors Multiples
Avadel Pharmaceuticals PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IE
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
773.1m USD 4.6 -15.8 -17.6 -16.5
US
Eli Lilly and Co
NYSE:LLY
779.4B USD 17.3 73.6 42.8 47.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
394B USD 4.4 28 13.1 17.2
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 7.2 20.8 13.7 15.6
CH
Roche Holding AG
SIX:ROG
236.5B CHF 4 20.6 11.5 13.6
UK
AstraZeneca PLC
LSE:AZN
177B GBP 4.2 32.6 126.9 193.9
US
Merck & Co Inc
NYSE:MRK
225.9B USD 3.5 13.2 8.9 10.5
CH
Novartis AG
SIX:NOVN
199.7B CHF 4.4 19 11.5 14.7
IE
Endo International PLC
LSE:0Y5F
167.6B USD 72.3 -57.3 267.5 670.8
US
Pfizer Inc
NYSE:PFE
142.8B USD 2.2 17.8 8.5 12.1
P/E Multiple
Earnings Growth PEG
IE
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Average P/E: 28.2
Negative Multiple: -15.8 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
73.6
49%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
28
26%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
20.8
19%
1.1
CH
Roche Holding AG
SIX:ROG
20.6
16%
1.3
UK
AstraZeneca PLC
LSE:AZN
32.6
36%
0.9
US
Merck & Co Inc
NYSE:MRK
13.2
18%
0.7
CH
Novartis AG
SIX:NOVN
19
16%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -57.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.8
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IE
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Average EV/EBITDA: 435.1
Negative Multiple: -17.6 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.8
30%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.1
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
15%
0.9
CH
Roche Holding AG
SIX:ROG
11.5
8%
1.4
UK
AstraZeneca PLC
LSE:AZN
126.9
9%
14.1
US
Merck & Co Inc
NYSE:MRK
8.9
9%
1
CH
Novartis AG
SIX:NOVN
11.5
5%
2.3
IE
E
Endo International PLC
LSE:0Y5F
267.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.5
3%
2.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IE
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Average EV/EBIT: 1 869.8
Negative Multiple: -16.5 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
47.2
33%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17.2
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
15.6
16%
1
CH
Roche Holding AG
SIX:ROG
13.6
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
193.9
21%
9.2
US
Merck & Co Inc
NYSE:MRK
10.5
12%
0.9
CH
Novartis AG
SIX:NOVN
14.7
8%
1.8
IE
E
Endo International PLC
LSE:0Y5F
670.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
12.1
10%
1.2

See Also

Summary
AVDL intrinsic value, competitors valuation, and company profile.
DCF Valuation
AVDL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AVDL stock valuation using valuation multiples.
Wall Street Estimates
AVDL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AVDL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 242,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.